TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an announcement.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for May 28, 2025, which will be held both physically and virtually. The meeting will address key resolutions including the approval of the 2024 annual report, financial statements, and remuneration plans for directors and supervisors. Additionally, a special resolution will be considered regarding the repurchase of H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. operates within the pharmaceutical industry, focusing on the development of innovative drugs and biotechnological solutions. The company is known for its work in the bio-medicine sector, particularly in Beijing’s Daxing Bio-Medicine Industry Park.
YTD Price Performance: 34.12%
Average Trading Volume: 186,043
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.54B
For an in-depth examination of 2315 stock, go to TipRanks’ Stock Analysis page.